Rashtriya Newsflash

Explore the comprehensive Generalized Myasthenia Gravis market report by a leading healthcare research firm, offering detailed insights, sales forecasts, and market analysis up to 2036.

Are you interested in finding out the projected market size of Generalized Myasthenia Gravis in 2036? Generalized Myasthenia Gravis Market Forecast

Key Factors Driving Generalized Myasthenia Gravis Market Growth1. Strong Market Growth and Revenue Projections

The gMG market across the 7MM was valued at approximately USD 5.9 billion in 2025 and is projected to expand at a CAGR of 9.1% through 2036, reaching approximately USD 15.6 billion.

Strong momentum is driven by targeted biologics, improved diagnosis through autoantibody testing, and sustained uptake across broader patient segments.

The United States accounted for approximately USD 4.7 billion in market size in 2025, representing the largest share among the 7MM.

Growing physician confidence is fueled by the transition from broad immunosuppression to mechanism-specific therapies, particularly FcRn inhibitors and complement inhibitors.

2. Expansion Across Targeted Patient Populations

Substantial Patient Base: In 2025, the United States accounted for approximately 90,000 diagnosed prevalent cases of gMG, underscoring a substantial patient base driving sustained demand.

Gender-Specific Distribution: Among gender-specific cases of gMG, the majority was occupied by females accounting for approximately 60% of the cases in the US in 2025.

Age Demographics: In 2025, the highest disease burden of gMG was observed in patients aged ≥65 years, accounting for approximately 108,000 cases across the 7MM, highlighting a predominantly elderly patient population.

Antibody Serology: In 2025, by antibody serology, Anti-AChR antibody-positive cases accounted for approximately 80% of patients with gMG in the EU4 and the UK, representing the dominant disease subtype.

Pipeline and lifecycle approaches, including next-generation FcRn blockers and complement inhibitors with improved durability and lifecycle protection, are expanding market penetration.

3. Paradigm Shift in Treatment Landscape

gMG management is transitioning from broad immunosuppression to targeted biologics such as VYVGART, RYSTIGGO, ZILBRYSQ, ULTOMIRIS, and IMAAVY driving mechanism-specific control and improved durability.

The loss of exclusivity of SOLIRIS has catalyzed the first meaningful biosimilar wave in gMG, introducing tangible pricing pressure and access expansion, while simultaneously accelerating strategic migration toward next-generation complement inhibitors.

Companies such as Immunovant, Alexion, Cartesian Therapeutics, Johnson & Johnson, Novartis, and others are advancing late-stage Phase III assets such as IMVT-1402, Gefurulimab, Descartes-08, Iptacopan, and MAVENCLAD.

Coupled with regulatory designations like ODD, FTD, Priority Review, and RMAT, these therapies are well-positioned to accelerate market growth and reshape the gMG treatment landscape.

The Generalized Myasthenia Gravis Market Report offers projected sales forecasts for gMG therapies until 2036, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products. It also covers analyst views along with market drivers and barriers.

What is Generalized Myasthenia Gravis?

Generalized Myasthenia Gravis (gMG) is an autoimmune disease in which the immune system attacks the body’s tissues. In myasthenia gravis, the attack interrupts the connection between nerve and muscle—the neuromuscular junction.

Myasthenia gravis is characterized by autoantibodies against the Acetylcholine Receptor Antibody (AChR-Ab) or against a receptor-associated protein called Muscle-specific tyrosine Kinase Antibody (MuSK-Ab).

The clinical diagnosis of gMG is confirmed by Electromyography (EMG) studies, pharmacologic testing, and serum Ab assay. EMG confirmation is crucial in patients with neither AChR nor MuSK Abs on the standard assay.

The report extensively covers the details and developments related to gMG therapies, capturing important highlights on developmental pipeline, regulatory status and special designations, route of administration, safety and efficacy details.

Generalized Myasthenia Gravis Market Assessment

This report provides a detailed market assessment of Generalized Myasthenia Gravis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2036.

Generalized Myasthenia Gravis Clinical Assessment

The report provides the clinical trials information of gMG therapies covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.

Do you know your drug’s competitive positioning in Generalized Myasthenia Gravis? gMG Drugs Insights

Generalized Myasthenia Gravis Recent Developments in the Treatment Landscape:

December 2025: Johnson & Johnson announced that the European Commission approved a Marketing Authorisation for IMAAVY (nipocalimab) as an add-on to standard therapy for gMG, making it the first FcRn blocker approved for both adults and adolescents aged 12 years and older who are anti-AChR or anti-MuSK antibody-positive.

December 2025: Immunovant reported the pricing of an underwritten common stock offering expected to generate approximately USD 550 million in gross proceeds, with Roivant Sciences, its controlling stockholder, committing to participate in the offering.

May 2025: UCB obtained approval from the Pharmaceuticals and Medical Devices Agency (PMDA) for rozanolixizumab to be self-administered at home by patients using either an infusion pump or a newly authorized manual push syringe technique.

December 2023: The EC approved ZILBRYSQ for the treatment of gMG in adult patients who are anti-AChR antibody-positive.

Generalized Myasthenia Gravis Competitive Landscape

The report offers insights into the key players and companies actively engaged in the development of therapies for gMG. It provides valuable information regarding the competitive positioning of therapies including VYVGART, RYSTIGGO, ZILBRYSQ, ULTOMIRIS, IMAAVY, IMVT-1402, Descartes-08, Gefurulimab, Iptacopan, and MAVENCLAD.

Generalized Myasthenia Gravis Market Size in the US

A dedicated section of the report focuses on the expected market size of gMG therapies for the United States. DelveInsight’s analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

Among the 7MM, the US accounted for the largest market size of gMG, i.e., approximately USD 4.7 billion in 2025.

Key Highlights of Generalized Myasthenia Gravis Market Report:

• The report contains forecasted sales of gMG therapies until 2036.

• Comprehensive coverage of the late-stage emerging therapies for Generalized Myasthenia Gravis.

• The report also features the qualitative and quantitative analysis with analysts as well as KOL views for gMG therapies.

• In 2036, among all the therapies for gMG, the highest revenue is estimated to be generated by efgartigimod alfa-fcab (VYVGART) in the 7MM.

Stay ahead in competition by leveraging insights on Generalized Myasthenia Gravis Market Report: Download gMG Market Report

Why You Should Buy Generalized Myasthenia Gravis Market Report:

The report provides future market assessments for gMG therapies in the 7 Major Markets, advanced qualitative analysis like SWOT and Conjoint Analysis, expert analysts’ views, detailed overview of market competitors, and comprehensive analysis of emerging therapies in Generalized Myasthenia Gravis.

Leading gMG forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the market.

Discover the competitive landscape of gMG therapies through 7MM: https://www.delveinsight.com/report-store/generalized-myasthenia-gravis-gmg-market?utm_source=abnewswire&utm_medium=druginsightpr&utm_campaign=mpr

Get a Thorough Analysis of the gMG Development pipeline, Safety & Efficacy, and Route of Administration

Thorough gMG market forecast will help understand how therapies are competing with other emerging treatments.

Get analysis of the gMG clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment.

Drug Market forecasts are calculated after taking into consideration KOL viewpoints from 8+ key opinion leaders across major markets including leading centers such as University of California and Royal College of Physicians.

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/generalized-myasthenia-gravis-gmg-market